Board summary
Key figures
20,927
Registered population
53.3% aged 18–64
31.3%
Aged 65+
ICB 19.0% · England 17.9%
2.9%
Ethnic minority (non-White)
1.0% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 31.9% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
3,882
Hypertension register
+6.59% in 3 yrs · England +5.60%
168
SMI register
4.5% of Cheshire West and Chester (LAD)'s
331
COPD register
Reviews +43.30% in 3 yrs
Forecast to 2030
4,529
Hypertension patients, 2030
+647 on today
73.3%
QRISK ≥20% on statins, 2030
+4.91pp over 3 yrs
8.1%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Under-80 blood pressure control trails despite high recording.
Under-80 blood pressure control is 63.7% (England 67.8%), down 1.6 pp over 2023 to 2025 (England +2.1 pp), despite 90.2% having a recent reading.
Asthma review coverage leaves about 660 patients unreviewed.
Annual asthma reviews reach 57.0% (England 65.7%), leaving about 660 of 1,525 register patients unreviewed alongside 2,811 items per 1,000 aged 5-19 (England 1,488).
Non-frail diabetes glycaemic control exceeds all comparators.
Non-frail diabetes HbA1c control at or below 58 mmol/mol reaches 65.6% against 57.5% in the borough, 56.2% in the ICB and 57.4% in England.
Population, age and ethnicity
Patients aged 65+ make up 31.3% of the list, consistent with high age-related demand
Neston & Willaston PCN serves 20,927 registered patients across three practices. On the registered list, patients aged 65+ make up 31.3% (6,549 patients), well above Cheshire West and Chester (LAD) at 20.3%, NHS Cheshire and Merseyside Integrated Care Board at 19.0%, and England at 17.9%. Children aged 0-17 represent 15.4% (LAD 18.5%, ICB 19.2%, England 19.6%). Based on Census usual residents rather than GP registrations, 97.1% identify as White (LAD 95.3%, ICB 93.0%, England 81.1%), with an ethnic minority share of 2.9%. Recorded learning disability prevalence is 0.5% (101 patients; England 0.6%).
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Cheshire West and Chester (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Cheshire West and Chester LA) | 2,109 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 82.2% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 65.6% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Cheshire West and Chester LA) | 893 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Cheshire West and Chester LA) | 14.9 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Average IMD decile is 7.6 with 0.0% Core20 patients across all three practices
The PCN average IMD decile is 7.6, indicating lower deprivation than Cheshire West and Chester (6.3), the ICB (5.2), and England (5.5). Registered Core20 share is 0.0% (0 estimated patients), below the borough (15.7%), the ICB (31.9%), and England (21.0%). Practice concentration reconciles with the PCN rate: Neston Surgery (decile 7.3), The Willaston Surgery (7.4), and Neston Medical Centre (7.5) each record 0.0% Core20. Area-based deprivation metrics cannot identify need in this catchment, so inequality efforts must focus on clinical inclusion groups.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
168
SMI register
0.80% recorded prevalence
101
Learning disability register
0.48% recorded prevalence
10
Care homes, 329 beds
In the PCN catchment
9.6%
Provide unpaid care
Cheshire West and Chester (LAD), Census 2021
Recorded severe mental illness prevalence is 0.8% (168 patients; LAD 1.0%, ICB 1.1%, England 1.0%), alongside 10 care homes with 329 catchment beds. Inclusion-health registers trail England, so proactive annual health checks and care-home coordination are key service priorities to protect.
Severe mental illness: physical health checks
BMI recording on the SMI register is 69.7% (England 82.1%), falling 6.7 pp over 2023 to 2025 (England +5.1 pp), including 67.2% at Neston Surgery and 51.9% at The Willaston Surgery. Alcohol recording is 64.8% (England 81.8%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
3,882
Hypertension register
+6.59%
Register growth, 3 yrs
Cheshire West and Chester (LAD) +6.60% · England +5.60%
−1.58pp
BP control, under 80
≤140/90 · −2.59pp aged 80+
+647
More patients by 2030
Forecast 4,529 (20.92%)
Hypertension case-finding and control
Hypertension prevalence is 18.4% (Cheshire West and Chester 17.0%, ICB 16.8%, England 15.2%), with recent blood pressure checks reaching 90.2% (England 90.0%). Blood pressure control in under-80s is 63.7%, trailing Cheshire West and Chester (66.3%), the ICB (66.4%) and England (67.8%), and fell 1.6 pp over 2023 to 2025 while England rose +2.1 pp. Overall treatment to target is 68.8% (England 70.3%). Control in under-80s diverges widely: Neston Medical Centre achieved 84.3%, while Neston Surgery reached 55.0% and The Willaston Surgery recorded 46.0%. Fewer hypertensive patients achieve clinical blood pressure control than national benchmarks indicate, so prioritising medication titration and adherence reviews across under-performing practices is warranted.
Lipids and statins
QRISK ≥ 20% lipid therapy reached 62.1% (England 63.6%), rising +4.9 pp over 2023 to 2025 (England +3.8 pp), and CKD lipid therapy is 69.8% (England 70.3%). Proactive cardiovascular risk review could improve lipid therapy uptake in high-risk groups.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 56,849 | £1.80 | £1.71 | £1.86 | £102,328 |
| Cardiovascular (all), 2025 | 71,838 | £5.60 | £4.37 | £3.33 | £402,293 |
In 2026, the PCN prescribed 56,849 lipid-regulating items at £1.80 per item (England £1.86, ICB £1.71). Across these 56,849 items, spend was £3,411 less than at England's unit cost, but £5,116 more than at ICB unit cost. Formulary review may identify opportunities to align spend with ICB benchmarks.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+19.46%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+3.08%
Asthma prevalence, PCN 3-yr % change
Asthma reviews reached 57.0% after rising +9.3 pp over 2023 to 2025 (England +2.8 pp), trailing England (65.7%) and leaving about 660 of 1,525 asthma patients without a recorded review. Asthma management prescribing is 2,811 items per 1,000 aged 5-19 (England 1,488). Recorded COPD prevalence is 1.6% (331 patients), below the borough (2.1%) and England (1.9%), presenting a benchmark gap range of +65 to +118 patients, while COPD reviews reach 71.0% (England 76.4%).
Cancer register and children's immunisation
The cancer register records 1,302 patients (6.2%, England 3.8%). For Q1 2025/26 childhood immunisations, age-5 MMR dose 1 coverage reached 100.0% (England 91.7%), but dose 2 dropped 10.3 pp to 89.7% (England 82.8%), falling 5.3 pp below the 95.0% target across 39 children. The second-dose gap was 14.3 pp at Neston Medical Centre and 8.3 pp at Neston Surgery.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
Neston & Willaston PCN records cancer prevalence of 6.2% (1,302 patients), with three-year growth of +14.2% (England +9.0%). PCN cervical screening is 74.2% (England 66.8%) and breast screening 75.9% (England 69.9%), though cervical coverage at The Willaston Surgery is 64.5%. In the wider system, 55.5% of ICB cancers with a known stage were diagnosed at stage 1 or 2 in 2022 (7,482 of 13,490; 72.8% staged), matching England (55.3%) but below the 75.0% ambition by 19.5 pp—a system gap of about 2,640 early cases. Tackling cervical screening variation between practices could help sustain early identification across the PCN.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
As wider-system provider context, in July 2026, Wirral University Teaching Hospital NHS Foundation Trust achieved 77.6% on the cancer 62-day referral to treatment standard, below the 85.0% standard by 7.4 pp, but ahead of Liverpool University Hospitals NHS Foundation Trust (73.3%), NHS Cheshire and Merseyside ICB (76.2%), and England (71.2%), while trailing Countess of Chester Hospital NHS Foundation Trust (83.3%). On the 28-day faster diagnosis standard, the trust reached 74.7% (England 79.3%). Across all diagnostic tests, 5.0% waited 6+ weeks (England 23.1%), though colonoscopy waits reached 32.8% (England 30.8%).
| Pathways within standard (%) | Wirral | Countess of Chester | Liverpool | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.71 | 87.37 | 75.47 | 77.25 | 79.32 |
| 31-day treatment (96%) | 92.53 | 93.48 | 90.51 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 77.65 | 83.28 | 73.26 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Wirral | Countess of Chester | Liverpool | England |
|---|---|---|---|---|
| MRI | 1.54 | 11.26 | 6.42 | 21.40 |
| CT | 1.55 | 4.18 | 0.71 | 9.92 |
| Echocardiography | 5.07 | 31.44 | 12.55 | 28.48 |
| Colonoscopy | 32.81 | 26.44 | 33.14 | 30.83 |
| Gastroscopy | 17.73 | 27.52 | 44.99 | 29.02 |
| All 15 DM01 tests | 5.02 | 20.16 | 11.50 | 23.14 |
| Community services activity | Cheshire West and Chester residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 47,655 | 541,280 |
| Referrals | 10,325 | 97,150 |
| Patients with a contact | 18,585 | 146,240 |
Community services (residents of Cheshire West and Chester), Jun 2026 (provisional). In June 2026, provisional community services data recorded 47,655 care contacts and 122,185 activities for Cheshire West and Chester residents, alongside 541,280 contacts and 1,332,205 activities across NHS Cheshire and Merseyside ICB. Adults aged 65+ accounted for 52.7% of borough contacts (25,095 contacts). These experimental figures reflect substantial older-age community demand, though activity was not captured for PCN registered patients.
Practice variation and patient experience
Practice phone access spans 19.8 pp and vaccination achievement diverges by 36.9 pp
Across England, overall 2025/26 QOF achievement is 92.5%. Neston Surgery achieves 97.2% and Neston Medical Centre reaches 96.9%, while The Willaston Surgery records 91.7%. Vaccination achievement spans 36.9 pp, from 98.4% at Neston Surgery to 61.5% at The Willaston Surgery. The Willaston Surgery also records a 13.4% personalised care adjustment rate (England 10.0%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Neston Surgery | 122 | 0.0 | 55.8% | 83.9% | 92.8% |
| Neston | 130 | 0.0 | 75.6% | 78.7% | 89.5% |
| Willaston | 124 | 0.0 | 59.4% | 74.6% | 77.2% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eleven of 25 three-year trends trail England, led by severe mental illness monitoring
Across 25 tracked three-year trends, 11 trail England. The sharpest deteriorations appear in severe mental illness monitoring: alcohol recording fell 15.9 pp to 64.8% (England +5.4 pp) and BMI recording fell 6.7 pp to 69.7% (England +5.1 pp). Blood pressure control in patients under 80 fell 1.6 pp to 63.7% (England +2.1 pp). In contrast, key process measures outpaced national growth: asthma reviews rose +9.3 pp to 57.0% (England +2.8 pp) and smoking cessation offers rose +4.2 pp to 98.0% (England +0.1 pp).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Alcohol record (psychosis)
BMI record (SMI)
BP control, under 80
BP control, 80+
Hypertension treated to target
COPD reviews
Asthma reviews
Smoking support (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Cheshire West and Chester (LAD) | Asset | PCN | Cheshire West and Chester (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 10 (329 beds) | n/a | Schools (catchment) | 20 | n/a |
| Children's centres | 1 | 15 | Places of worship | 18 | 231 |
| Libraries | 2 | 16 | Food banks (VCS) | n/a | 1 |
| Homelessness support (VCS) | n/a | 1 | Day centres (VCS) | n/a | 1 |
| Carers support groups (VCS) | n/a | 1 | Primary schools (LA maintained) | 6 | 70 |
| Primary academies | 1 | 46 | Special schools | n/a | 5 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension titration and CVD prescribing review
Under-80 BP control is 63.7% (England 67.8%; fell 1.6 pp vs England +2.1 pp), QRISK ≥ 20% lipid therapy is 62.1% (England 63.6%), and CVD spend is £163,072 more than England's unit cost across 71,838 items. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Structured asthma review and prescribing recall
Annual asthma review coverage is 57.0% vs 65.7% in England (8.7 pp below), leaving 656 (about 660) of 1,525 patients unreviewed, alongside 2,811 items per 1,000 aged 5-19 (England 1,488). For discussion: align annual asthma recall with repeat inhaler prescribing reviews, offering after-school slots for children and young people. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
COPD case-finding and annual review audit
Recorded COPD prevalence is 1.6% (331 patients) vs 1.9% in England and 2.1% in the borough, a benchmark gap of +65 to +118 patients, with annual reviews at 71.0% (England 76.4%). Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Learning disability register audit (p2) | Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Inclusion health targeting review (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall audit (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension medication titration review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR recall tracking (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening recall (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | Practice |
| Telephony and triage access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Hypertension titration and CVD prescribing review (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 2 · Structured asthma review and prescribing recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · COPD case-finding and annual review audit (p12) | COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 months | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
